RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML

National Institute of Cancerología

Status: Unknown

Conditions: Acute Myeloblastic Leukemia; Acute Lymphoblastic Leukemia.

Study type: Observational

Funder types: Other

Identifiers

NCT01307241

010/020/ICI

Details and patient eligibility

About

Results of actual treatment in ALL are not optimal. New prognostic factors, which may determine clinical & molecular response are required. Hyper-CVAD is an internationally accepted schema for such patients. The objective of this pilot study is to evaluate polymorphisms regarding RFC (reduced folate carrier) and MTHFR enzyme, which may affect the function of these proteins, and therefore the intracellular bioavailability of methotrexate. Also, the expression levels of hENT1 and dCK will be evaluated, since such genes codify for citarabine intracellular transport and activation, respectively. Clinical characteristics will be tabulated and analyzed for responders & non-responders patients. Uni- & multivariate analysis will be done to evaluate factors influencing on response and survival.

Enrollment: 50 estimated patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age: older than 15 years.
• Male, female.
• Normal renal & liver functions.
• Without previous treatment.
• Candidate to be treated with hyperCVAD Schema (ALL patients).
• Candidate to receive induction remission with cytarabine (AML patients)

Exclusion criteria

• Patients not candidate to receive methotrexate or cytarabine.

Trial design

50 participants in 1 patient group

one cohort

Description:

Adult patients with ALL attending at the Instituto Nacional de Cancerologia Mexico.